Loading
Macrophage Activation Syndrome: An Atypical Initial Presentation of Systemic Lupus Erythematosus
Macrophage Activation Syndrome (MAS) is a severe inflammatory complication often linked to autoimmune disorders such as systemic lupus erythematosus (SLE). We describe a 57-year-old woman who presented with persistent fever, polyarthralgia, pancytopenia, and markedly elevated ferritin levels (>40,000 ng/mL). Extensive evaluation ruled out infection and malignancy. A diagnosis of MAS was made, and she responded well to high-dose corticosteroids and anakinra.
Interleukin-1 Inhibitors for Acute Gout Flares: A Systematic Review and Meta-analysis
Acute gout flares cause severe pain, and conventional therapies are often contraindicated. Interleukin-1 (IL-1) inhibitors offer a targeted mechanism, but their efficacy and safety profile require systematic evaluation. This PRISMA-adherent systematic review and meta-analysis of 10 randomized controlled trials (n=1,731) assessed the efficacy and safety of IL-1 inhibitors (anakinra, canakinumab, rilonacept) versus active comparators or placebo.
Unveiling Primary Angiitis of the Central Nervous System: A Systematic Review of Presentations and Mimics
Primary angiitis of the central nervous system (PACNS) is a rare form of single-organ vasculitis, as classified by the 2012 Chapel Hill Consensus Conference. It affects small- and medium-sized vessels within the brain and spinal cord, arises independently of systemic disease, manifests with heterogeneous clinical features, and remains without definitive diagnostic biomarkers.
Towards an AI-enabled, mTOR-targeted and Regenerative Care Model for Gout and Osteoarthritis in China
To evaluate therapeutic innovations for chronic joint diseases (gout and osteoarthritis [OA]) in China, focusing on mechanistic target of rapamycin (mTOR) inhibitors, mesenchymal stem cell (MSC) therapy, and AI-enhanced health-care models, and to propose a multidisciplinary framework optimizing disease management while addressing health-care disparities.
Dual Benefit of Methotrexate in Psoriatic Arthritis and Myasthenia Gravis: A Case Report
Psoriatic arthritis (PsA) is a chronic inflammatory condition affecting approximately 30% of individuals with psoriasis, while myasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by antibodies targeting acetylcholine receptors, leading to progressive muscle weakness. Although autoimmune diseases often coexist, concurrent presentation of PsA and MG is exceedingly rare and poorly documented.